Longeveron (LGVN) Share-based Compensation (QoQ) (2020 - 2026)
Longeveron (LGVN) Share-based Compensation (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.80% |
| Dec 31, 2025 | -16.07% |
| Sep 30, 2025 | -12.67% |
| Jun 30, 2025 | 50.88% |
| Mar 31, 2025 | -12.82% |
| Dec 31, 2024 | -72.40% |
| Sep 30, 2024 | 514.35% |
| Jun 30, 2024 | -22.03% |
| Mar 31, 2024 | -28.57% |
| Dec 31, 2023 | -17.23% |
| Sep 30, 2023 | -28.61% |
| Jun 30, 2023 | 66.03% |
| Mar 31, 2023 | -34.83% |
| Dec 31, 2022 | 29.20% |
| Sep 30, 2022 | -44.44% |
| Jun 30, 2022 | 83.30% |
| Mar 31, 2022 | -92.01% |
| Dec 31, 2021 | 146.15% |
| Sep 30, 2021 | 12.48% |
| Jun 30, 2021 | 1,764.71% |